BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Suppression of inflammation in psoriasis blood after IL-17 treatment with ixekizumab

Dataset: Suppression of inflammation in psoriasis blood after IL-17 treatment with ixekizumab

The effect of anti-IL-17 treatment on systemic inflammation is not fully understand. Using cDNA microarray, genomic analysis methods such...

Registered by ArrayExpress Uploader
View Dataset

The effect of anti-IL-17 treatment on systemic inflammation is not fully understand. Using cDNA microarray, genomic analysis methods such as GSEA and ingenuity, we characterized the transcriptional changes in the blood of psoriasis patients afer systemic neutralization of IL-17 compared to baseline (before treatment). We also compared the whole blood-derived transcriptome between psoraisis patients at baseline and healthy volunteers to examine systemic inflammation in psoriasis patients. total RNA was extratced from whole blood from psoriasis patients at baseline and after two weeks of treatment; total RNA was extracted from the whole blood of healthy individuals

Species:
human

Samples:
81

Source:
E-GEOD-55201

Updated:
Dec.12, 2014

Registered:
Jul.11, 2014


Factors: (via ArrayExpress)
Sample TIME SUBJECT ID SUBJECT CONDITION SAMPLE GROUP
GSM1331534 week 2, after ixekizumab 150mg subcutaneous treatment 1803 psoriasis patients Psoriasis treatment
GSM1331533 week 2, after ixekizumab 150mg subcutaneous treatment 1710 psoriasis patients Psoriasis treatment
GSM1331532 week 2, after ixekizumab 150mg subcutaneous treatment 1615 psoriasis patients Psoriasis treatment
GSM133153 week 2, after ixekizumab 150mg subcutaneous treatment 1611 psoriasis patients Psoriasis treatment
GSM1331530 week 2, after ixekizumab 150mg subcutaneous treatment 1209 psoriasis patients Psoriasis treatment
GSM1331529 week 2, after ixekizumab 150mg subcutaneous treatment 1208 psoriasis patients Psoriasis treatment
GSM1331528 week 2, after ixekizumab 150mg subcutaneous treatment 1207 psoriasis patients Psoriasis treatment
GSM1331527 baseline; before treatment 1803 psoriasis patients Psoriasis Baseline
GSM1331526 baseline; before treatment 1710 psoriasis patients Psoriasis Baseline
GSM1331525 baseline; before treatment 1615 psoriasis patients Psoriasis Baseline
GSM1331524 baseline; before treatment 1611 psoriasis patients Psoriasis Baseline
GSM1331523 baseline; before treatment 1610 psoriasis patients Psoriasis Baseline
GSM1331522 baseline; before treatment 1209 psoriasis patients Psoriasis Baseline
GSM133152 baseline; before treatment 1208 psoriasis patients Psoriasis Baseline
GSM1331520 baseline; before treatment 1207 psoriasis patients Psoriasis Baseline
GSM1331519 baseline; before treatment 1902 psoriasis patients Psoriasis Baseline
GSM1331518 baseline; before treatment 1707 psoriasis patients Psoriasis Baseline
GSM1331517 baseline; before treatment 1706 psoriasis patients Psoriasis Baseline
GSM1331516 baseline; before treatment 1612 psoriasis patients Psoriasis Baseline
GSM1331515 baseline; before treatment 1609 psoriasis patients Psoriasis Baseline
GSM1331514 baseline; before treatment 1608 psoriasis patients Psoriasis Baseline
GSM1331513 baseline; before treatment 1607 psoriasis patients Psoriasis Baseline
GSM1331512 baseline; before treatment 1109 psoriasis patients Psoriasis Baseline
GSM13315 baseline; before treatment 1801 psoriasis patients Psoriasis Baseline
GSM1331510 baseline; before treatment 1606 psoriasis patients Psoriasis Baseline
GSM1331509 baseline; before treatment 1505 psoriasis patients Psoriasis Baseline
GSM1331508 baseline; before treatment 1410 psoriasis patients Psoriasis Baseline
GSM1331507 baseline; before treatment 1404 psoriasis patients Psoriasis Baseline
GSM1331506 baseline; before treatment 1403 psoriasis patients Psoriasis Baseline
GSM1331505 baseline; before treatment 1402 psoriasis patients Psoriasis Baseline
GSM1331504 baseline; before treatment 1401 psoriasis patients Psoriasis Baseline
GSM1331503 baseline; before treatment 1605 psoriasis patients Psoriasis Baseline
GSM1331502 baseline; before treatment 1504 psoriasis patients Psoriasis Baseline
GSM133150 baseline; before treatment 1502 psoriasis patients Psoriasis Baseline
GSM1331500 baseline; before treatment 1303 psoriasis patients Psoriasis Baseline
GSM1331499 baseline; before treatment 1301 psoriasis patients Psoriasis Baseline
GSM1331498 baseline; before treatment 1104 psoriasis patients Psoriasis Baseline
GSM1331497 baseline; before treatment 1102 psoriasis patients Psoriasis Baseline
GSM1331496 baseline; before treatment 1604 psoriasis patients Psoriasis Baseline
GSM1331495 baseline; before treatment 1603 psoriasis patients Psoriasis Baseline
GSM1331494 baseline; before treatment 1602 psoriasis patients Psoriasis Baseline
GSM1331493 baseline; before treatment 1601 psoriasis patients Psoriasis Baseline
GSM1331492 baseline; before treatment 1205 psoriasis patients Psoriasis Baseline
GSM133149 baseline; before treatment 1702 psoriasis patients Psoriasis Baseline
GSM1331490 baseline; before treatment 1614 psoriasis patients Psoriasis Baseline
GSM1331489 baseline; before treatment 1613 psoriasis patients Psoriasis Baseline
GSM1331488 baseline; before treatment 1507 psoriasis patients Psoriasis Baseline
GSM1331487 baseline; before treatment 1503 psoriasis patients Psoriasis Baseline
GSM1331486 baseline; before treatment 1405 psoriasis patients Psoriasis Baseline
GSM1331485 baseline; before treatment 1304 psoriasis patients Psoriasis Baseline
GSM1331484 baseline; before treatment 1108 psoriasis patients Psoriasis Baseline
GSM1331483 not specified 11855 healthy volunteer Healthy Control
GSM1331482 not specified 11854 healthy volunteer Healthy Control
GSM133148 not specified 11853 healthy volunteer Healthy Control
GSM1331480 not specified 11852 healthy volunteer Healthy Control
GSM1331479 not specified 11851 healthy volunteer Healthy Control
GSM1331478 not specified 11850 healthy volunteer Healthy Control
GSM1331477 not specified 11849 healthy volunteer Healthy Control
GSM1331476 not specified 11848 healthy volunteer Healthy Control
GSM1331475 not specified 11847 healthy volunteer Healthy Control
GSM1331474 not specified 11846 healthy volunteer Healthy Control
GSM1331473 not specified 11824 healthy volunteer Healthy Control
GSM1331472 not specified 11823 healthy volunteer Healthy Control
GSM133147 not specified 11822 healthy volunteer Healthy Control
GSM1331470 not specified 11821 healthy volunteer Healthy Control
GSM1331469 not specified 11820 healthy volunteer Healthy Control
GSM1331468 not specified 11819 healthy volunteer Healthy Control
GSM1331467 not specified 11818 healthy volunteer Healthy Control
GSM1331466 not specified 11817 healthy volunteer Healthy Control
GSM1331465 not specified 11816 healthy volunteer Healthy Control
GSM1331464 not specified 11815 healthy volunteer Healthy Control
GSM1331463 not specified 11699 healthy volunteer Healthy Control
GSM1331462 not specified 11698 healthy volunteer Healthy Control
GSM133146 not specified 11697 healthy volunteer Healthy Control
GSM1331460 not specified 11696 healthy volunteer Healthy Control
GSM1331459 not specified 11695 healthy volunteer Healthy Control
GSM1331458 not specified 11694 healthy volunteer Healthy Control
GSM1331457 not specified 11693 healthy volunteer Healthy Control
GSM1331456 not specified 11692 healthy volunteer Healthy Control
GSM1331455 not specified 11691 healthy volunteer Healthy Control
GSM1331454 not specified 11690 healthy volunteer Healthy Control

Tags

  • psoriasis

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2025 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use